Dernières nouvelles pour Mesoblast (NASDAQ:MESO) Stock

Mesoblast

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Limited - American Depositary Shares

Mesoblast Ltd

Meso Numismatics Inc

<p>German stocks are crushing Wall Street this year, recording their strongest outperformance against U.S. equities since 1999 — a market dynamic that last emerged just before the infamous burst of <a href="https://www.benzinga.com/money/stocks-to-buy-now">the dot-com bubble.</a></p>
<p>Through June 20, Germany's DAX Index has climbed 17.5% year-to-date, while the <strong>Vanguard S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) has gained only 1.9%. </p>
<p>The six-month performance spread between the two benchmarks now stands at nearly 16 percentage points — the highest gap since the second half of 1999.</p>
<p>Currency effects further amplified the gains. The <strong>iShares MSCI Germany Index Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWG#NYSE">EWG</a>) – a U.S.-listed ETF tracking German equities and adjusting for exchange rate moves — has soared 28% year-to-date, as the U.S. dollar weakened 10% against the euro.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20090757/DAX_SPX_2025-06-20_13-47-14_65bbe-1024x528.png" alt="" class="wp-image-956067" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20090757/DAX_SPX_2025-06-20_13-47-14_65bbe-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20090757/DAX_SPX_2025-06-20_13-47-14_65bbe-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20090757/DAX_SPX_2025-06-20_13-47-14_65bbe-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20090757/DAX_SPX_2025-06-20_13-47-14_65bbe-1536x792.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20090757/DAX_SPX_2025-06-20_13-47-14_65bbe-2048x1056.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<h3 class="wp-block-heading">Why Are German Stocks Outperforming?</h3>
<p>A mix of aggressive fiscal expansion, monetary easing, and global investor rotation has put Germany at the center of a rare equity resurgence.</p>
<p>In March 2025, Germany's Parliament approved a constitutional amendment that exempts military and infrastructure spending from the country's strict "debt brake" law. </p>
<p>This legal shift enabled the government to create a massive €500 billion ($565 billion) infrastructure fund, aimed at financing green energy, digitalization, and regional development through 2035 — all off-budget to bypass constitutional debt limits.</p>
<p>Additionally, Germany committed to raising defense spending well beyond 3% of GDP — aligning with NATO&#8217;s Readiness 2030 and the broader €800 billion ($900 billion) ReArm Europe plan. This military push has sparked investor enthusiasm in defense stocks and industrial suppliers.</p>
<p>At the same time, the European Central Bank has aggressively cut rates by a cumulative 75 basis points during the first half of 2025, bringing the deposit rate down to 2% in June, amid cooling inflation.</p>
<p>Meanwhile, the U.S. market has faced headwinds. President <strong>Donald Trump</strong>'s aggressive tariff push fueled trade uncertainty and triggered a first-quarter GDP contraction, as businesses rushed to import goods ahead of higher duties set for April.</p>
<p>The Federal Reserve has kept interest rates unchanged in a 4.25%-4.50% range, despite declining inflation.</p>
<h3 class="wp-block-heading">Rheinmetall Leads The Charge</h3>
<p>A handful of key outperformers have driven Germany's stock rally.</p>
<p>Defense heavyweight <strong>Rheinmetall AG </strong>(OTCPK: RNMBF) is up a staggering 181% year-to-date, contributing 356 basis points to the DAX's total year-to-date return. </p>
<p>Other top gainers include <strong>Siemens Energy AG </strong>(OTCPK: SMEGF), up 71.7%, <strong>Commerzbank AG </strong>(OTCPK: CRZBY), up 83%, and <strong>Deutsche Bank AG</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>), which has gained 47%, each providing significant contributions to index performance.</p>
<h3 class="wp-block-heading">History Echoes 1999?</h3>
<p>The last time German stocks outpaced their U.S. counterparts this sharply was in late 1999. Then, too, global investors rotated into European equities amid optimism about reforms and tech-driven growth. </p>
<p>Yet that outperformance came at the height of global market euphoria: the S&amp;P 500 peaked at 1,550 in March 2000, then plunged 45% over the following three years. </p>
<p>Whether 2025's surge ends in sustained growth or a speculative overshoot remains to be seen. </p>
<p>But for now, Germany is among the leaders in global equity markets — and echoing the late 1990s in ways that seasoned investors may not want to forget.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/news/health-care/25/06/45997946/stock-market-strategy-investing-analysis-healthcare-stocks-united-health">Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake</a></strong><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></span></li>
</ul>
<p><em>Photo: FOTOGRIN/Shutterstock</em></p>


Eurozone

Global

Econ #s

CRZBY

RNMBF

SMEGF

This Rare Market Dynamic Preceded The Dot-Com Crash — It's Back In 2025

<p>RBC Capital  analyst Scott Hanold   reiterates EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Outperform and maintains $145 price target.</p>


News

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on EOG Resources, Maintains $145 Price Target

<p>JP Morgan  analyst Paul Coster   maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Overweight and raises the price target from $12 to $13.</p>


ARRY

JP Morgan Maintains Overweight on Array Technologies, Raises Price Target to $13

<p>RBC Capital  analyst Leonid Timashev   reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Outperform and raises the price target from $13 to $17.</p>


CRMD

RBC Capital Reiterates Outperform on Cormedix, Raises Price Target to $17

Politics

General

iShares MSCI Israel Capped Investable Market Index Fund

Reuters Citing UK Government Saying Due To The Security Situation, UK Staff Have Been Temporarily Withdrawn From Iran. Our Embassy Continues To Operate Remotely

<p>Shares of <strong>Gorilla Technology Group Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) soared 40.6% to $26.45 on Friday afternoon following a robust first-quarter earnings report that showed significant revenue growth and a <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46007657/gorilla-technology-stock-surges-on-q1-earnings-as-momentum-builds">return to profitability</a>.</p>
<p><strong>What To Know:</strong> The company posted revenue of $18.26 million, marking a 109% increase from $8.74 million in the same period last year. This surge was attributed to a series of new global agreements.</p>
<p>Earnings came in at 23 cents per share, a notable turnaround from a loss of $1.47 per share in the prior year's quarter. However, this figure represents a 41% drop from the 39 cents per share reported in the same quarter last year, reflecting adjusted metrics.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/crypto/25/06/46021402/peter-schiff-says-he-intends-to-launch-gold-backed-stablecoins-deems-dollar-as-a-flawed-fiat-currency">Peter Schiff Says He Intends To Launch Gold-Backed Stablecoins, Deems Dollar As A &#8216;Flawed&#8217; Fiat Currency</a></strong></p>
<p>Gorilla Technology ended the quarter with $33.8 million in cash, including $20.8 million in restricted funds. The company also <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46007657/gorilla-technology-stock-surges-on-q1-earnings-as-momentum-builds">reported</a> a deal pipeline exceeding $5 billion, signaling confidence in future growth.</p>
<p>"This quarter is not just a performance milestone &#8211; it is proof of trajectory," said CEO <strong>Jay Chandan</strong>. He emphasized the company's accelerating momentum, global expansion, and deepening partnerships.</p>
<p>The strong results and bullish outlook have investors optimistic as the stock trends across social media platforms during Friday&#8217;s session.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/equities/25/06/46023273/walmart-snaps-10-day-losing-streak-its-longest-since-2004-as-profit-takers-step-aside">Walmart Snaps 10-Day Losing Streak: It&#8217;s Longest Since 2004, As Profit-Takers Step Aside</a></strong></p>
<h2 class="wp-block-heading">How To Buy GRRR Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Gorilla Tech&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, GRRR has a 52-week high of $44.15 and a 52-week low of $2.09.</p>
<p><em>Image: Shutterstock</em></p>


GRRR

Gorilla Technology (GRRR) Stock Surges On Strong Revenue Growth, Profit Turnaround

<p>Financial giants have made a conspicuous bearish move on Meta Platforms. Our analysis of options history for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) revealed 50 unusual trades.</p>
<p>Delving into the details, we found 24% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 19 were puts, with a value of $1,272,016, and 31 were calls, valued at $1,702,513.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $860.0 for Meta Platforms, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Meta Platforms's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Meta Platforms's whale activity within a strike price range from $5.0 to $860.0 in the last 30 days. </p>
<h3>Meta Platforms Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428110_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/27/25</td>
<td>$11.15</td>
<td>$11.1</td>
<td>$11.1</td>
<td>$700.00</td>
<td>$221.3K</td>
<td>1.8K</td>
<td>203</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$18.5</td>
<td>$18.35</td>
<td>$18.5</td>
<td>$695.00</td>
<td>$166.5K</td>
<td>579</td>
<td>188</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$23.05</td>
<td>$22.75</td>
<td>$22.9</td>
<td>$500.00</td>
<td>$146.5K</td>
<td>7.4K</td>
<td>64</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.75</td>
<td>$3.6</td>
<td>$3.66</td>
<td>$695.00</td>
<td>$134.4K</td>
<td>2.1K</td>
<td>4.1K</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$63.05</td>
<td>$62.6</td>
<td>$62.6</td>
<td>$640.00</td>
<td>$125.2K</td>
<td>1.1K</td>
<td>21</td>
</tr>
</tbody>
</table>
</p>
<h3>About Meta Platforms</h3>
<p>Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.</p>
<p>Having examined the options trading patterns of Meta Platforms, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Meta Platforms Standing Right Now?</h3>
<ul>
<li>With a trading volume of 3,324,965, the price of META is down by 0.0%, reaching $695.78.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 40 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Meta Platforms</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $723.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Meta Platforms, maintaining a target price of $735.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Meta Platforms, which currently sits at a price target of $664.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $676.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Meta Platforms, maintaining a target price of $765.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Meta Platforms, which currently sits at a price target of $775. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Meta Platforms, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Smart Money Is Betting Big In META Options

<p>Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 23% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $609,596, and 4 were calls, valued at $150,651.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $900.0 for Eli Lilly over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $300.0 to $900.0 in the last 30 days. </p>
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428104_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$14.75</td>
<td>$10.8</td>
<td>$12.72</td>
<td>$775.00</td>
<td>$236.8K</td>
<td>686</td>
<td align="right">379</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$25.0</td>
<td>$19.9</td>
<td>$22.63</td>
<td>$780.00</td>
<td>$83.0K</td>
<td>1.3K</td>
<td align="right">553</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$127.65</td>
<td>$122.15</td>
<td>$124.94</td>
<td>$900.00</td>
<td>$74.9K</td>
<td>196</td>
<td align="right">7</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$31.75</td>
<td>$30.55</td>
<td>$30.55</td>
<td>$760.00</td>
<td>$61.1K</td>
<td>364</td>
<td align="right">38</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$482.15</td>
<td>$475.1</td>
<td>$478.61</td>
<td>$300.00</td>
<td>$47.8K</td>
<td>53</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
</p>
<h3>About Eli Lilly</h3>
<p>Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.</p>
<p>In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>Currently trading with a volume of 1,003,032, the LLY's price is down by -3.48%, now at $757.73. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $936.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Guggenheim has revised its rating downward to Buy, adjusting the price target to $936. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Looking At Eli Lilly's Recent Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Visa</strong>.</p>
<p>Looking at options history for Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 44% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $522,743 and 2, calls, for a total amount of $61,516.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $340.0 to $360.0 for Visa over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Visa's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Visa's whale activity within a strike price range from $340.0 to $360.0 in the last 30 days. </p>
<h3>Visa Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428098_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$15.55</td>
<td>$15.05</td>
<td>$15.3</td>
<td>$350.00</td>
<td>$119.3K</td>
<td>2.9K</td>
<td align="right">96</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$21.95</td>
<td>$21.7</td>
<td>$21.7</td>
<td>$355.00</td>
<td>$97.6K</td>
<td>336</td>
<td align="right">45</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$22.1</td>
<td>$21.9</td>
<td>$21.9</td>
<td>$355.00</td>
<td>$96.3K</td>
<td>336</td>
<td align="right">139</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$21.75</td>
<td>$21.35</td>
<td>$21.58</td>
<td>$355.00</td>
<td>$82.7K</td>
<td>336</td>
<td align="right">90</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$15.4</td>
<td>$15.05</td>
<td>$15.4</td>
<td>$350.00</td>
<td>$55.4K</td>
<td>2.9K</td>
<td align="right">133</td>
</tr>
</tbody>
</table>
</p>
<h3>About Visa</h3>
<p>Visa is the largest payment processor in the world. In fiscal 2024, it processed almost $16 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.</p>
<p>Following our analysis of the options activities associated with Visa, we pivot to a closer look at the company's own performance.</p>
<h3>Visa's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 3,050,684, the V's price is down by -0.24%, now at $339.56. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 32 days.</li>
</ul>
<h3>Professional Analyst Ratings for Visa</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $410.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Mizuho upgraded its action to Outperform with a price target of $425.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on Visa with a target price of $410.<br />
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $400.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Visa with a target price of $405. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Visa options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Spotlight on Visa: Analyzing the Surge in Options Activity

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) in the last three months.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $943.0, a high estimate of $1124.00, and a low estimate of $700.00. This current average represents a 8.7% decrease from the previous average price target of $1032.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428075_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Eli Lilly is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$936.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Rajesh Kumar</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$700.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$975.00</td>
<td>-</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$928.00</td>
<td>$973.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1124.00</td>
<td>$1146.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$888.00</td>
<td>$892.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eli Lilly. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Eli Lilly's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Eli Lilly's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LLY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Eli Lilly analyst ratings.</strong></a></p>
<h2>Discovering Eli Lilly: A Closer Look</h2>
<p>Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.</p>
<h3>Eli Lilly's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Eli Lilly showcased positive performance, achieving a revenue growth rate of <strong>45.17%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Eli Lilly's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>21.68%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Eli Lilly's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>18.42%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Eli Lilly's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.28%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Eli Lilly's debt-to-equity ratio surpasses industry norms, standing at <strong>2.44</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 7 Analyst Projections For Eli Lilly

<p>Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) underwent analysis by 27 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">4</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Enphase Energy, revealing an average target of $50.04, a high estimate of $78.00, and a low estimate of $31.00. Highlighting a 22.36% decrease, the current average has fallen from the previous average price target of $64.45. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428064_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Enphase Energy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Sophie Karp</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$39.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Lowers</td>
<td>Sell</td>
<td>$31.11</td>
<td>$50.69</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Sell</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$49.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$58.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$36.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Sean Milligan</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$37.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Christopher Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$54.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$77.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$46.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$51.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Sell</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Jeffrey Osborne</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$78.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Sean Milligan</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$44.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Enphase Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Enphase Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Enphase Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Enphase Energy's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ENPH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Enphase Energy analyst ratings.</strong></a></p>
<h2>All You Need to Know About Enphase Energy</h2>
<p>Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.</p>
<h3>Financial Milestones: Enphase Energy's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Enphase Energy's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>35.22%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Enphase Energy's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>8.35%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Enphase Energy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.62%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Enphase Energy's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.94%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.49</strong>, Enphase Energy faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ENPH

Analyst Expectations For Enphase Energy's Future

<p>4 analysts have expressed a variety of opinions on Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.75, a high estimate of $117.00, and a low estimate of $64.00. This current average reflects an increase of 0.54% from the previous average price target of $77.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428056_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Ultragenyx Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Sami Corwin</td>
<td>William Blair</td>
<td>Announces</td>
<td>Outperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ultragenyx Pharmaceutical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Ultragenyx Pharmaceutical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RARE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</strong></a></p>
<h2>All You Need to Know About Ultragenyx Pharmaceutical</h2>
<p>Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.</p>
<h3>Breaking Down Ultragenyx Pharmaceutical's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Ultragenyx Pharmaceutical's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>27.99%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of <strong>-108.46%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ultragenyx Pharmaceutical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-75.63%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ultragenyx Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-10.73%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Ultragenyx Pharmaceutical's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.27</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RARE

Ultragenyx Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<p><strong>Jerash Holdings (US)</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) is set to give its latest quarterly earnings report on Monday, 2025-06-23. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Jerash Holdings (US) will report an <strong>earnings per share</strong> (EPS) of $0.04. </p>
<p>The announcement from Jerash Holdings (US) is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.01 in the last quarter, leading to a 1.09% increase in the share price on the following day.</p>
<p>Here's a look at Jerash Holdings (US)'s past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>0</td>
<td>0.08</td>
<td>-0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0</td>
<td>0.05</td>
<td>-0.11</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-0.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428054_0.png" alt="eps graph" /></p>
<h3>Jerash Holdings (US) Share Price Analysis</h3>
<p>Shares of Jerash Holdings (US) were trading at $3.27 as of June 19. Over the last 52-week period, shares are up 9.93%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/JRSH/earnings"><strong>To track all earnings releases for Jerash Holdings (US) visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

JRSH

Earnings Outlook For Jerash Holdings (US)

<p>Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.57, a high estimate of $100.00, and a low estimate of $65.00. This current average has increased by 3.66% from the previous average price target of $76.76. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428043_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Cameco among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Wong</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.27</td>
<td>$75.27</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$65.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cameco. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cameco compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Cameco's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cameco's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CCJ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Cameco analyst ratings.</strong></a></p>
<h2>About Cameco</h2>
<p>Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.</p>
<h3>Financial Milestones: Cameco's Journey</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Cameco's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>24.61%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Cameco's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.84%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Cameco's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.09%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Cameco's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.72%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.15</strong>, Cameco adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Cameco Stock: Analyst Perspectives (4 Ratings)

<p>FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) will release its quarterly earnings report on Monday, 2025-06-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate FactSet Research Systems to report an <strong>earnings per share</strong> (EPS) of $4.30.</p>
<p>FactSet Research Systems bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.10, which was followed by a 0.45% increase in the share price the next day.</p>
<p>Here's a look at FactSet Research Systems's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>4.18</td>
<td>4.28</td>
<td>3.62</td>
<td>3.90</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>4.28</td>
<td>4.37</td>
<td>3.74</td>
<td>4.37</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428033_0.png" alt="eps graph" /></p>
<h3>Performance of FactSet Research Systems Shares</h3>
<p>Shares of FactSet Research Systems were trading at $425.04 as of June 19. Over the last 52-week period, shares are up 0.68%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on FactSet Research Systems</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on FactSet Research Systems.</p>
<p>With 3 analyst ratings, FactSet Research Systems has a consensus rating of Neutral. The average one-year price target is $472.33, indicating a potential 11.13% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Morningstar, MarketAxess Holdings and Tradeweb Markets, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Morningstar, with an average 1-year price target of $355.0, suggesting a potential 16.48% downside.</li>
<li>Analysts currently favor an Neutral trajectory for MarketAxess Holdings, with an average 1-year price target of $238.56, suggesting a potential 43.87% downside.</li>
<li>Analysts currently favor an Buy trajectory for Tradeweb Markets, with an average 1-year price target of $169.4, suggesting a potential 60.14% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>In the peer analysis summary, key metrics for Morningstar, MarketAxess Holdings and Tradeweb Markets are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>FactSet Research Systems</td>
<td>Neutral</td>
<td>4.53%</td>
<td>$301.06M</td>
<td>7.16%</td>
</tr>
<tr>
<td>Morningstar</td>
<td>Outperform</td>
<td>7.20%</td>
<td>$350.50M</td>
<td>4.86%</td>
</tr>
<tr>
<td>MarketAxess Holdings</td>
<td>Neutral</td>
<td>-0.83%</td>
<td>$142.47M</td>
<td>1.10%</td>
</tr>
<tr>
<td>Tradeweb Markets</td>
<td>Buy</td>
<td>24.70%</td>
<td>$332.80M</td>
<td>2.53%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>FactSet Research Systems ranks in the middle for revenue growth among its peers. It has the highest gross profit margin. The company's return on equity is higher than two peers but lower than one. Overall, FactSet Research Systems is performing well compared to its peers in terms of gross profit and return on equity.</p>
<h3>Get to Know FactSet Research Systems Better</h3>
<p>FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for roughly 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.</p>
<h3>Key Indicators: FactSet Research Systems's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining FactSet Research Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.53%</strong> as of 28 February, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> FactSet Research Systems's net margin is impressive, surpassing industry averages. With a net margin of <strong>25.38%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> FactSet Research Systems's ROE excels beyond industry benchmarks, reaching <strong>7.16%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> FactSet Research Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.49%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> FactSet Research Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.81</strong>.</p>
<p><a href="https://www.benzinga.com/quote/FDS/earnings"><strong>To track all earnings releases for FactSet Research Systems visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FactSet Research Systems's Earnings Outlook

<p><strong>Honeywell Intl's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HON#NYSE">HON</a>) short percent of float has fallen 7.63% since its last report. The company recently reported that it has <strong>7.01 million shares sold short</strong>, which is 1.09% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.8 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Honeywell Intl Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428032_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Honeywell Intl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Honeywell Intl's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Honeywell Intl's peer group average for short interest as a percentage of float is 5.29%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Is Honeywell Intl Gaining or Losing Market Support?

<p>Across the recent three months, 8 analysts have shared their insights on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.75, a high estimate of $81.00, and a low estimate of $4.00. This current average has decreased by 34.38% from the previous average price target of $56.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428030_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Prothena Corp is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$29.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$78.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Prothena Corp's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Prothena Corp analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Prothena Corp</h2>
<p>Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.</p>
<h3>Financial Insights: Prothena Corp</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Prothena Corp displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>5556.0%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-2128.54%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Prothena Corp's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-13.02%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Prothena Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-11.55%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.02</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PRTA

8 Analysts Assess Prothena Corp: What You Need To Know

<p><strong>Arthur J. Gallagher's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) short percent of float has fallen 7.43% since its last report. The company recently reported that it has <strong>3.68 million shares sold short</strong>, which is 1.62% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.58 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Arthur J. Gallagher Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428026_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Arthur J. Gallagher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Arthur J. Gallagher's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Arthur J. Gallagher's peer group average for short interest as a percentage of float is 2.99%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


What's Driving the Market Sentiment Around Arthur J. Gallagher?

<p>The S&amp;P 500 index growth sans the Magnificent 7 stocks is almost negligible over the last 10 years, as the market capitalization of these stocks dominates the index.</p>
<p><strong>What Happened: </strong>According to a <strong>Goldman Sachs</strong> graph shared by the Markets &amp; Mayhem, the Magnificent 7 stocks have driven the S&amp;P 500 growth since 2014, with their index rising from 500 to over 3500.</p>
<p>While the remaining 493 stocks stagnated near 500, reflecting a 2024 study by Goldman Sachs showing the stocks accounted for over 30% of the S&amp;P 500&#8217;s <a href="https://www.goldmansachs.com/insights/articles/is-the-sp-too-concentrated">market cap</a>. </p>
<p>This concentration aligns with the Pareto principle, where 20% of assets drive 80% of returns, supported by a 2018 ScienceDirect <a href="https://www.sciencedirect.com/science/article/abs/pii/S0378437105001950">study</a> on stock market indices that found power-law distributions in extreme variations, suggesting the Magnificent 7&#8217;s dominance is a natural outcome of market-cap weighting rather than an anomaly.<br /><br />Thus, according to this graph, if an investor invested in the S&amp;P 500, excluding the Magnificent 7 stocks, they&#8217;d have virtually negligible returns. </p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Wow. If you net out the Mag 7 from the S&amp;P 500, the remaining 493 stocks have barely gone anywhere in over a decade (comparatively speaking).<br /><br />Chart: Goldman Sachs <a href="https://t.co/0q8kYpA3St">https://t.co/0q8kYpA3St</a> <a href="https://t.co/RE2RDL8ZcP">pic.twitter.com/RE2RDL8ZcP</a></p>
<p>&mdash; Markets &amp; Mayhem (@Mayhem4Markets) <a href="https://twitter.com/Mayhem4Markets/status/1931060432821010860?ref_src=twsrc%5Etfw">June 6, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Filip Felician Dames,</strong> the founder of a venture capital fund, Cherry Ventures, explained that the research and development, or R&amp;D spending, by Magnificent 7 stocks was a significant determinant of the company&#8217;s &#8220;future earnings power.&#8221;</p>
<p>&#8220;We need more innovation and risk-taking mentality,&#8221; he added.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">R&amp;D spend is a main predictor of future earnings power. Today, Mag7 are investing more in R&amp;D than all listed companies in Europe put together. We need more innovation and risk-taking mentality to narrow the gap. <a href="https://twitter.com/WSJ?ref_src=twsrc%5Etfw">@WSJ</a> <a href="https://twitter.com/WSJTech?ref_src=twsrc%5Etfw">@WSJTech</a></p>
<p>&mdash; Filip Dames (@filipdames) <a href="https://twitter.com/filipdames/status/1935673496295657883?ref_src=twsrc%5Etfw">June 19, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Meanwhile, looking at the valuation of these seven firms using the price-to-sales ratio, <strong>Amazon.com Inc.</strong> was the cheapest at 0.38, while <strong>Microsoft Corp.</strong> was the most expensive at 0.92.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Among the biggest AI names, <a href="https://twitter.com/search?q=%24AMZN&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMZN</a> seems to be the cheapest Mag 7, even beating <a href="https://twitter.com/search?q=%24GOOGL&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOGL</a>. <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a> is priced in pretty decent already IMO. <a href="https://t.co/3dsqPTDVrg">pic.twitter.com/3dsqPTDVrg</a></p>
<p>&mdash; Ravi (@ravisRealm) <a href="https://twitter.com/ravisRealm/status/1934458417072267758?ref_src=twsrc%5Etfw">June 16, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>See Also: <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is &#8216;Massively Underestimating&#8217; This AI Play, Urges Investors To Look Beyond Mag 7</a></strong></p>
<p><strong>Why It Matters:</strong> Comparatively, the Magnificent 7 stocks haven&#8217;t performed well in 2025. Only <strong>Nvidia Corp.</strong>, Microsoft, and <strong>Meta Platforms Inc.</strong> beat the -1.33% year-to-date return of the Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>) and the 1.91% return of the S&amp;P 500 index.</p>
<p><figure class="wp-block-table is-style-stripes"><br />
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Stocks</strong></td>
<td><strong>YTD Performance</strong></td>
<td><strong>One-Year Performance</strong></td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>5.18%</td>
<td>11.24%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>-19.38%</td>
<td>-6.25%</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>14.73%</td>
<td>7.75%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-3.50%</td>
<td>14.20%</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</td>
<td>-8.73%</td>
<td>-2.10%</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>16.11%</td>
<td>38.68%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>-15.09%</td>
<td>77.37%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">More Mag 7 relative strength.. best since Feb 20 <a href="https://twitter.com/search?q=%24MAGS&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MAGS</a> <a href="https://t.co/0rmrrrp1Qf">pic.twitter.com/0rmrrrp1Qf</a></p>
<p>&mdash; Mike Zaccardi, CFA, CMT &#x1f356; (@MikeZaccardi) <a href="https://twitter.com/MikeZaccardi/status/1934705246451675484?ref_src=twsrc%5Etfw">June 16, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, the <strong>SPDR S&amp;P 500 ETF Trust </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was trading above its short and long-term simple dialing moving averages with a relative strength index at 57.35, which was in a neutral zone.</p>
<p>Despite the largely bullish chart, its momentum indicator was reflecting a key bearish crossover signal as its MACD line of 7.1 was below the signal line of 8.3 with a negative histogram value of 1.2.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20032837/SPY-stock-tech-new-1024x576.png" alt="" class="wp-image-955591" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20032837/SPY-stock-tech-new-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20032837/SPY-stock-tech-new-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20032837/SPY-stock-tech-new-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20032837/SPY-stock-tech-new-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20032837/SPY-stock-tech-new.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Price Action:</strong> The<strong> </strong>SPY and <strong>Invesco QQQ Trust ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.</p>
<p>On Friday, the futures of the S&amp;P 500, Dow Jones, and the Nasdaq 100 indices were trading lower.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/markets/equities/25/06/46016347/this-stock-just-popped-30-in-5-days-now-expert-says-it-looks-potentially-explosive">This Stock Just Popped 30% In 5 Days — Now Expert Says It &#8216;Looks Potentially Explosive&#8217;</a></strong></li>
</ul>
<p><em>Photo courtesy: Jack Hong / Shutterstock.com</em></p>


Equities

AAPL

AMZN

GOOG

MAGS

MSFT

NVDA

TSLA

What If You Invested In S&P 500 Excluding Mag 7? Here's How NVDA, AMZN, AAPL And Others Have Performed In The Last Year

<p>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) will release its quarterly earnings report on Monday, 2025-06-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate KB Home to report an <strong>earnings per share</strong> (EPS) of $2.23.</p>
<p>The market awaits KB Home's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.10, leading to a 5.21% drop in the share price on the subsequent day.</p>
<p>Here's a look at KB Home's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.59</td>
<td>2.44</td>
<td>2.05</td>
<td>1.80</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.49</td>
<td>2.52</td>
<td>2.04</td>
<td>2.15</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>5.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750428021_0.png" alt="eps graph" /></p>
<h3>Market Performance of KB Home's Stock</h3>
<p>Shares of KB Home were trading at $50.62 as of June 19. Over the last 52-week period, shares are down 28.94%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analysts' Perspectives on KB Home</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding KB Home.</p>
<p>Analysts have provided KB Home with 9 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $63.56, suggesting a potential 25.56% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Champion Homes, Cavco Indus and Meritage Homes, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Champion Homes, with an average 1-year price target of $83.67, suggesting a potential 65.29% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Cavco Indus, with an average 1-year price target of $550.0, suggesting a potential 986.53% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Meritage Homes, with an average 1-year price target of $76.33, suggesting a potential 50.79% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Champion Homes, Cavco Indus and Meritage Homes, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>KB Home</td>
<td>Neutral</td>
<td>-5.18%</td>
<td>$282.82M</td>
<td>2.67%</td>
</tr>
<tr>
<td>Champion Homes</td>
<td>Neutral</td>
<td>10.72%</td>
<td>$152.45M</td>
<td>2.37%</td>
</tr>
<tr>
<td>Cavco Indus</td>
<td>Neutral</td>
<td>21.00%</td>
<td>$116.12M</td>
<td>3.42%</td>
</tr>
<tr>
<td>Meritage Homes</td>
<td>Neutral</td>
<td>-7.17%</td>
<td>$302.38M</td>
<td>2.38%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>KB Home ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. KB Home is at the bottom for Return on Equity.</p>
<h3>Delving into KB Home's Background</h3>
<p>KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.</p>
<h3>Understanding the Numbers: KB Home's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> KB Home's revenue growth over a period of 3 months has faced challenges. As of 28 February, 2025, the company experienced a revenue decline of approximately <strong>-5.18%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>7.82%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.67%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> KB Home's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.56%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.44</strong>.</p>
<p><a href="https://www.benzinga.com/quote/KBH/earnings"><strong>To track all earnings releases for KB Home visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview: KB Home

Press Releases

Ryoncil® is Now Available for Purchase in the United States

Health Care

First Three Children to Commence Treatment With Ryoncil®

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Management

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

ADIA

CRSP

FATE

MESO

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

Beam Therapeutics

Biohaven

CareDx

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MannKind

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Comments

Mesoblast

Actualités

Dernières nouvelles pour Mesoblast (NASDAQ:MESO) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL